qxd 18 2 04 3:58 PM Page 1 AstraZeneca Annual Report and Contents Form 20-F Information 2003 Contents Cross Reference to The information in this document that is r Key Achievements 01 Financial Statements 21.
Reserves 86 with the Securities and Exchange Comm Chairmans Statement 02 Preparation of the Financial Statements 22.
Net cash inflow from into any filings by AstraZeneca under the and Directors Responsibilities 60 trading operations 87 Global Market Overview 03 such major headings, including subhead Basis of Consolidation and Presentation 23.
Cash flows related Chief Executives Review 04 Graphs are not included unless specifica of Financial Information 60 to exceptional items 87 Financial Highlights 05 SEC passed comment upon the accurac Independent Auditors Report to the 24.
Acquisitions of subsidiaries and Board of Directors 06 information and may be updated from tim Members of AstraZeneca PLC 61 purchases of minority interests 87 Strategy 08 Group Profit and Loss Account 62 25.
Disposals of business operations 88 Operational Review 09 Group Statement of Total Recognised 26.
Reconciliation of net cash flow Item Cardiovascular 10 Gains and Losses 62 to movement in net funds 88 3 Key Information Gastrointestinal 12 Group Balance Sheet 64 27.
Selected financial data Neuroscience 14 Statement of Group Cash Flow 65 28. Financing 89 Financial Highlights Oncology 16 Accounting Policies 66 29.
Post-retirement benefits 90 Group Financial Record Respiratory and Inflammation 18 Notes to the Financial Statements 30.
Employee costs and share option Shareholder Information Infection 20 plans for employees 95 D. Risk factors 1.
Group operating profit 68 Geographic Review 21 31.
Share of turnover and operating 4 Information on the Company and contingent liabilities 100 Research and Development 23 profits of joint ventures and associates 68 32.
History and development Development Pipeline 24 Financial Review Investm 3.
Statutory and other information 107 Commercialisation and and capital expenditure Portfolio Management 26 4.
Company information 108 Note 9 Tangible fixed ass Supply and Manufacturing 27 5.
Called-up share capital Note 24 Acquisitions of s of parent company 111 Other Businesses, Main Facilities 6.
Dividends to shareholders 74 purchases of minority inte and Intellectual Property 28 Principal Subsidiaries 112 Note 25 Disposals of bu 7.
Earnings per $0.25 Ordinary Share 74 Industry Regulation 29 B.
Business overview Additional Information for 8.
Segment information 75 Operational Review US Investors 113 Corporate Responsibility 30 9.
Tangible fixed assets 77 C. Organisational structure Group Financial Record UK GAAP 124 Financial Review 31 10.
Goodwill and intangible assets 77 Directors Report Group Financial Record US GAAP 126 Directors Report 43 11.
Fixed asset investments 78 Principal Subsidiaries Shareholder Information 127 Audit Committees Report 48 D. Property, plant and equipm 12.
Stocks 78 Risk Factors 135 Operational Review Mai Directors Remuneration Report 50 13.
Debtors 79 AstraZeneca Code of Conduct 138 14.
Short term investments 79 5 Operating and Financial Revie Additional Information 140 15.
Short term borrowings and A-F. Financial Review Cross Reference to Form 20-F inside overdrafts 79 back cover 16.
Other creditors 80 6 Directors, Senior Managemen 17.
Financial instruments 81 Board of Directors and Off 19.
Provisions for liabilities and charges 85 B.
Reconciliation of movements C. Board practices in shareholders funds 85 Board of Directors and Off Directors Remuneration R Directors Report Audit Committees Report D. Employees Note 30 Employee costs plans for employees Directors Report Emplo Trade marks our sales revenue to competitors and total market the forward-looking statements by using the words E. Share ownership Trade marks of the AstraZeneca group sales revenues for that period.
anticipates, believes, expects, intends and similar Directors Remuneration R of companies appear throughout this document in expressions in such statements.
These forwardDirectors Interests in Sha italics.
AstraZeneca, the AstraZeneca logotype and the Statements of growth rates looking statements are subject to numerous risks and AstraZeneca symbol are all trade marks of the Except as otherwise stated, growth rates in this uncertainties.
Important factors that could cause AstraZeneca group of companies.
Annual Report and Form 20-F Information 2003 are actual results to differ materially from those contained 7 Major Shareholders and Relat given at constant exchange rates CER.
in forward-looking statements, certain of which are A.
Major shareholders Use of terms beyond our control, include, among other things: the In this Annual Report and Form 20-F Information 2003, AstraZeneca website loss or expiration of patents, marketing exclusivity or Shareholder Information unless the context otherwise requires, AstraZeneca, Information on our website, astrazeneca.
com, does trade marks: exchange rate fluctuations: the risk that B.
Related party transactions the Group, the Company, we, us and our refer not form part of this document.
R&D will not yield new products that achieve Shareholder Information to AstraZeneca PLC and its consolidated entities.
commercial success: the impact of competition, price transactions Cautionary statement regarding forward-looking controls and price reductions: taxation risks: the risk of Note 33 Statutory and o Statements of competitive position statements substantial product liability claims: the impact Except as otherwise stated, market information In order to utilise the safe harbour provisions of the of any failure by third parties to supply materials 8 Financial Information in this Annual Report and Form 20-F Information 2003 US Private Securities Litigation Reform Act 1995, we or services: the risk of delay to new product launches: regarding the position of our business or products are providing the following cautionary statement: This the difficulties of obtaining and maintaining A.
Consolidated statements relative to its or their competition is based upon Annual Report and Form 20-F Information 2003 governmental approvals for products: and the risk of financial information published statistical data for the 12 months ended contains certain forward-looking statements about environmental liabilities.
Financial Statements exc 30 September 2003, or the month of November 2003, AstraZeneca.
Although we believe our expectations responsibilities on page 60 obtained from IMS Health, a leading supplier of are based on reasonable assumptions, any forwardopinion on page 61 statistical data to the pharmaceutical industry.
Except looking statements may be influenced by factors that as otherwise stated, this market share and industry could cause actual outcomes and results to be B.
Significant changes data from IMS Health has been derived by comparing materially different from those predicted.
